Scinai Immunotherapeutics Ltd. - American Depositary Shares (SCNI)

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company operating a contract development and manufacturing organization (“CDMO”) alongside an immunotherapy development platform, announced securities purchase and warrant inducement agreements with an existing institutional investor expected to generate approximately $4 million in aggregate gross proceeds. The private placement includes 2,458,334 American Depositary Shares (“ADSs”), or pre-funded warrants in lieu thereof, together with warrants to purchase up to 3,687,501 additional ADSs, at a combined purchase price of $1.20 per ADS and accompanying warrants. Under the warrant inducement agreement, the investor will immediately exercise existing warrants covering 879,194 ADSs at a reduced exercise price of $1.20 per ADS and receive new warrants to purchase up to 1,318,791 ADSs. The transactions are expected to close on or about Oct. 15, 2026, subject to customary conditions.

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company operating a growing contract development and manufacturing organization (CDMO) alongside an immunology-focused therapeutic development platform, announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., has entered into a definitive development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company. The agreement expands an existing customer relationship and includes approximately $5.1 million in committed base service fees, subject to performance and contractual terms. The engagement covers development and clinical manufacturing services for an investigational oncology product, with revenue expected during 2026 and 2027 and stability services extending beyond 2027.

September 14, 2026 In drug development, identifying a dangerous compound is only half the challenge. The other is avoiding the premature elimination of a potentially valuable medicine. VivoSim Labs, Inc. (NASDAQ: VIVS) is targeting both problems with its NAMkind™ 3D human tissue models and predictive toxicology platform .

Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company combining immunology therapeutic development with a revenue-generating contract development and manufacturing organization (“CDMO”), announced a strategic refocusing of its R&D portfolio following the Aug. 31 expiration and termination of its option and license arrangements with PinCell S.r.l. relating to PC111. Scinai said the decision was not driven by any new negative scientific finding regarding PC111 and will allow the company to concentrate R&D resources on its NanoAb platform while preserving capital and management capacity for its CDMO business. Scinai is advancing two IL-17 programs within the NanoAb platform, including an intradermal psoriasis program for which approximately €12 million in grant financing is under evaluation in Poland. The company also reported approximately $3.1 million in committed CDMO customer orders as of Aug. 16 and continues to pursue approximately $5 million in CDMO revenue for 2026, subject to project execution, timing, revenue recognition and additional business opportunities.

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company combining therapeutic development with a revenue-generating contract development and manufacturing organization (“CDMO”), reported first-half 2026 revenue of $949,000, up from $773,000 in the prior-year period, while committed customer orders reached approximately $3.1 million as of Aug. 16, 2026, including approximately $2.1 million already invoiced. The company is also advancing an expanded clinical manufacturing and chemistry, manufacturing and controls (“CMC”) program for a U.S.-based biopharmaceutical company, with approximately $650,000 in cash payments and advances received and substantive activities underway while a definitive agreement remains under negotiation. The program is intended to support an investigational drug product toward a U.S. investigational new drug (“IND”) submission and Phase III clinical development. Scinai continues to pursue approximately $5 million in CDMO revenue for 2026.

Scinai Immunotherapeutics (NASDAQ: SCNI) announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., has appointed Eran Kuratz as head of supply chain and business process administration. Kuratz brings more than 30 years of leadership, supply chain and operational experience across the pharmaceutical, biotechnology, medical-device and industrial sectors. He will oversee functions including procurement, contracting, inventory management, logistics, budgeting, IT and business systems, cybersecurity and cross-functional business processes.